<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30039622</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1349-7006</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>109</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer science</Title>                <ISOAbbreviation>Cancer Sci.</ISOAbbreviation>            </Journal>            <ArticleTitle>Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>3272-3284</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.13748</ELocationID>            <Abstract>                <AbstractText>Acetylation plays an important role in regulating the chaperone activity of heat shock protein 90 (Hsp90) during malignant transformation through the stabilization and conformational maturation of oncogenic proteins. However, the functional acetylation sites, potential anticancer drug targets, are still emerging. We found that acetylation at K292 in Hsp90α is critical for the development and treatment of breast cancer. Acetylation at K292 not only augments the affinity of Hsp90 to ATP, cochaperones, and client proteins but it also promotes cancer cell colony formation, migration, and invasion in vitro as well as tumor growth in vivo. Importantly, K292-acetylated Hsp90 has been validated as an exciting anticancer drug target by interfering with the complex formation between K292-acetylated Hsp90 and cochaperone Cdc37, leading to diminishment of kinase client maturation and proteasome-dependent degradation of kinase substrates. Furthermore, we showed that simvastatin prevented, whereas LBH589 promoted, the progression of Hsp90 chaperone cycling and client maturation, resulting in an increment of cell apoptosis by the combination of simvastatin and LBH589 in a mouse xenograft model. These data suggest that simvastatin is a novel Hsp90 inhibitor to disrupt the formation of the K292-acetylated Hsp90/Cdc37 complex in triple-negative breast cancer cells. The combination of simvastatin with LBH589 could be used as a novel therapeutic strategy for triple-negative breast cancer.</AbstractText>                <CopyrightInformation>© 2018 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kou</LastName>                    <ForeName>Xinhui</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Endocrine and Department of Pharmacy, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Biochemistry, School of Pharmacy, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jiang</LastName>                    <ForeName>Xiaoxiao</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Biochemistry, School of Pharmacy, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Huijuan</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Biochemistry, School of Pharmacy, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Xuan</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Biochemistry, School of Pharmacy, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Fanghui</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Biochemistry, School of Pharmacy, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Han</LastName>                    <ForeName>Jiami</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Biochemistry, School of Pharmacy, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fan</LastName>                    <ForeName>Jiaxing</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Biochemistry, School of Pharmacy, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Feng</LastName>                    <ForeName>Guize</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Biochemistry, School of Pharmacy, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lin</LastName>                    <ForeName>Zhaohu</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Chemical Biology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jiang</LastName>                    <ForeName>Lan</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biological Sciences, Oakland University, Rochester, Michigan, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Yonghua</ForeName>                    <Initials>Y</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8451-1083</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Biochemistry, School of Pharmacy, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>81272391</GrantID>                    <Agency>National Natural Science Foundation of China</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>81572721</GrantID>                    <Agency>National Natural Science Foundation of China</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cancer Sci</MedlineTA>            <NlmUniqueID>101168776</NlmUniqueID>            <ISSNLinking>1347-9032</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C498362">CDC37 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C533585">HSP90alpha protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>8L70Q75FXE</RegistryNumber>                <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>9647FM7Y3Z</RegistryNumber>                <NameOfSubstance UI="C496932">panobinostat</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>AGG2FN16EV</RegistryNumber>                <NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 3.6.1.-</RegistryNumber>                <NameOfSubstance UI="D018833">Chaperonins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>K3Z4F929H6</RegistryNumber>                <NameOfSubstance UI="D008239">Lysine</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Exp Med. 2012 Apr 9;209(4):697-711</RefSource>                <PMID Version="1">22451720</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Mol Life Sci. 2014 Oct;71(20):3885-901</RefSource>                <PMID Version="1">24898083</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2014 Jan;124(1):30-9</RefSource>                <PMID Version="1">24382387</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2010 Aug;10(8):537-49</RefSource>                <PMID Version="1">20651736</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2005 Feb 15;105(4):1768-76</RefSource>                <PMID Version="1">15514006</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5017-22</RefSource>                <PMID Version="1">25852146</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS Med. 2010 May 25;7(5):e1000279</RefSource>                <PMID Version="1">20520800</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Jan 30;7:41615</RefSource>                <PMID Version="1">28134290</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2008 Jun 15;68(12):4833-42</RefSource>                <PMID Version="1">18559531</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell. 2007 Jan 12;25(1):151-9</RefSource>                <PMID Version="1">17218278</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Jan 5;7(1):946-60</RefSource>                <PMID Version="1">26503475</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell. 2011 Aug 19;43(4):572-85</RefSource>                <PMID Version="1">21855797</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2008 Jan;7(1):162-70</RefSource>                <PMID Version="1">18202019</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Dis. 2014 Feb 20;5:e1070</RefSource>                <PMID Version="1">24556685</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2009 Jan 15;28(2):157-69</RefSource>                <PMID Version="1">18931700</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell. 2016 Apr 21;62(2):260-271</RefSource>                <PMID Version="1">27105117</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Struct Mol Biol. 2013 Jan;20(1):1-4</RefSource>                <PMID Version="1">23288357</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2009 Dec 18;284(51):35381-9</RefSource>                <PMID Version="1">19858214</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2005 Jul 22;280(29):26729-34</RefSource>                <PMID Version="1">15937340</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2011 Aug 15;17(16):5432-42</RefSource>                <PMID Version="1">21715568</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2012 Aug 31;150(5):987-1001</RefSource>                <PMID Version="1">22939624</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Med Chem. 2012 Mar;4(4):505-24</RefSource>                <PMID Version="1">22416777</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Mar 14;8(11):17833-17848</RefSource>                <PMID Version="1">28147319</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast. 2013 Oct;22(5):569-78</RefSource>                <PMID Version="1">23870456</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochim Biophys Acta. 2012 Mar;1823(3):648-55</RefSource>                <PMID Version="1">21856339</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Biochem Sci. 2015 Feb;40(2):117-25</RefSource>                <PMID Version="1">25579468</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2018 Oct;109(10):3272-3284</RefSource>                <PMID Version="1">30039622</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2013 Aug;14(9):e358-69</RefSource>                <PMID Version="1">23896275</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Top Med Chem. 2016;16(25):2753-64</RefSource>                <PMID Version="1">27072696</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018833" MajorTopicYN="N">Chaperonins</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018841" MajorTopicYN="N">HSP90 Heat-Shock Proteins</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006877" MajorTopicYN="N">Hydroxamic Acids</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cdc37</Keyword>            <Keyword MajorTopicYN="N">Hsp90</Keyword>            <Keyword MajorTopicYN="N">LBH589</Keyword>            <Keyword MajorTopicYN="N">acetylation</Keyword>            <Keyword MajorTopicYN="N">simvastatin</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30039622</ArticleId>            <ArticleId IdType="doi">10.1111/cas.13748</ArticleId>            <ArticleId IdType="pmc">PMC6172049</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>